Clinical Trial

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

Study acronym: RAVEN
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-02-17; most recent amendment 2024-01-08.
Status change: Not Yet Recruiting → Recruiting 2022-03-23
Trial Details
NCT Number NCT05246345
Lead Sponsor University Hospital, Clermont-Ferrand
Conditions Chronic Lymphocytic Leukemia, CLL, Progressive Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia
Enrollment 50 participants
Start Date 2022-03-07
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-01-09